Elstner E, Linker-Israeli M, Said J, Umiel T, de Vos S, Shintaku I P, Heber D, Binderup L, Uskokovic M, Koeffler H P
Division of Hematology-Oncology, University of California, School of Medicine 90048, USA.
Cancer Res. 1995 Jul 1;55(13):2822-30.
We have studied the in vitro biological activities and mechanism of action of 1,25-dihydroxyvitamin D3 (1,25D3) and four potent 1,25D3 analogues [20-epi-22oxa-24a,26a,27a-tri-homo-1,25(OH)2D3 (KH 1060); 20-epi-1,25(OH)2D3; 1,25(OH)2-16ene-D3; and 1,25(OH)2-16ene-23yne-D3] on proliferation and differentiation of estrogen receptor-negative (MDA-MB-436, BT-20, SK-BR-3, and MDA-MB-231), estrogen receptor-weakly positive (BT474), and estrogen receptor-positive (MCF-7) breast cancer cell lines. Dose-response studies showed that KH 1060 was the most potent analogue, because it was able to induce differentiation in all seven breast cancer cell lines (measured by lipid staining) and to suppress more than 50% clonal proliferation (ED50) at 10(-10) M in all cell lines, except MDA-MB-436 and BT-20. To explore how these compounds mediated antiproliferative actions, their effects on the cell cycle, on expression of bcl-2 and p53, and on apoptosis were assessed. Five of six cell lines have a mutant p53 gene, whereas MCF-7 has wild-type p53. Immunohistochemical staining showed that the p53 protein was predominantly localized in the nucleus in each of the breast cancer cell lines except for MCF-7, which expressed the protein predominantly in the cytoplasm. After incubation with KH 1060 (3 days; 10(-7) M), expression of bcl-2 protein as determined by immunohistochemical localization was markedly decreased in BT-474, MCF-7, and MDA-MB-231; these same cells were profoundly inhibited in their clonal proliferation and arrested in the G0/G1 phase of the cell cycle when cultured with KH 1060. In contrast, BT-20 and MDA-MB-436 cells that were refractory to the antiproliferative effect of KH 1060 (ED50 < 10(-6) M) had no down-regulation of their bcl-2 expression and no cell cycle changes after exposure to KH 1060. MCF-7 showed morphological changes and DNA fragmentation, indicative of apoptosis after 48 h incubation with KH 1060 (10(-6) M), during which time p53 protein accumulated in the nucleus and decreased in the cytoplasm. In contrast, no apoptosis was detected in three other breast lines (MDA-MB-231, SK-BR-3, and BT-474) that had a mutated p53. In conclusion, the data indicate that KH 1060 is an extremely potent 1,25D3 analogue inducing differentiation of all six breast cancer lines and potently inhibiting clonal growth of four of them with concomitant decreased bcl-2 and cell cycle arrest at G0/G1.(ABSTRACT TRUNCATED AT 400 WORDS)
我们研究了1,25 - 二羟基维生素D3(1,25D3)及四种有效的1,25D3类似物[20 - 表 - 22 - 氧杂 - 24a,26a,27a - 三高 - 1,25(OH)2D3(KH 1060);20 - 表 - 1,25(OH)2D3;1,25(OH)2 - 16 - 烯 - D3;以及1,25(OH)2 - 16 - 烯 - 23 - 炔 - D3]对雌激素受体阴性(MDA - MB - 436、BT - 20、SK - BR - 3和MDA - MB - 231)、雌激素受体弱阳性(BT474)和雌激素受体阳性(MCF - 7)乳腺癌细胞系增殖和分化的体外生物学活性及作用机制。剂量反应研究表明,KH 1060是最有效的类似物,因为它能够在所有七种乳腺癌细胞系中诱导分化(通过脂质染色测定),并在除MDA - MB - 436和BT - 20外的所有细胞系中,在10^(-10) M浓度下抑制超过50%的克隆增殖(ED50)。为探究这些化合物如何介导抗增殖作用,评估了它们对细胞周期、bcl - 2和p53表达以及凋亡的影响。六个细胞系中有五个具有突变型p53基因,而MCF - 7具有野生型p53。免疫组织化学染色显示,除MCF - 7主要在细胞质中表达p53蛋白外,p53蛋白在其他每个乳腺癌细胞系中主要定位于细胞核。用KH 1060(3天;10^(-7) M)孵育后,通过免疫组织化学定位测定,BT - 474、MCF - 7和MDA - MB - 231中bcl - 2蛋白的表达明显降低;当用KH 1060培养时,这些相同的细胞在克隆增殖中受到显著抑制,并停滞在细胞周期的G0/G1期。相比之下,对KH 1060的抗增殖作用具有抗性(ED50 < 10^(-6) M)的BT - 20和MDA - MB - 436细胞,在暴露于KH 1060后,其bcl - 2表达没有下调,细胞周期也没有变化。用KH 1060(10^(-6) M)孵育48小时后,MCF - 7显示出形态变化和DNA片段化,表明发生了凋亡,在此期间p53蛋白在细胞核中积累,在细胞质中减少。相比之下,在另外三个具有突变型p53的乳腺癌细胞系(MDA - MB - 231、SK - BR - 3和BT - 474)中未检测到凋亡。总之,数据表明KH 1060是一种极其有效的1,25D3类似物,可诱导所有六种乳腺癌细胞系分化,并有效抑制其中四种细胞系的克隆生长,同时伴随bcl - 2表达降低和细胞周期停滞在G0/G1期。(摘要截断于400字)